Affordable Access

Access to the full text

Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19

Authors
  • van de Veerdonk, Frank L.1, 2
  • Kouijzer, Ilse J. E.1, 2
  • de Nooijer, Aline H.1
  • van der Hoeven, Hans G.3
  • Maas, Coen4
  • Netea, Mihai G.1, 2, 5
  • Brüggemann, Roger J. M.2, 6
  • 1 Radboudumc Institute for Molecular Life Sciences, Department of Internal Medicine, Radboudumc, Nijmegen, the Netherlands
  • 2 Radboudumc Center for Infectious Diseases, Nijmegen, the Netherlands
  • 3 Department of Intensive Care Medicine, Radboudumc, Nijmegen, the Netherlands
  • 4 Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, the Netherlands
  • 5 Life and Medical Sciences Institute, Department for Genomics & Immunoregulation, University of Bonn, Bonn, Germany
  • 6 Radboud Institute for Health Sciences, Department of Pharmacy, Radboudumc, Nijmegen, the Netherlands
Type
Published Article
Journal
JAMA Network Open
Publisher
American Medical Association
Publication Date
Aug 13, 2020
Volume
3
Issue
8
Identifiers
DOI: 10.1001/jamanetworkopen.2020.17708
PMID: 32789513
PMCID: PMC7426743
Source
PubMed Central
Disciplines
  • Infectious Diseases
License
Green
External links

Abstract

This case-control study examines the association between receipt of the bradykinin 2 (B2) receptor antagonist icatibant and improved oxygenation in patients with coronavirus disease 2019 (COVID-19).

Report this publication

Statistics

Seen <100 times